Per Ljungman

Summary

Affiliation: Huddinge University Hospital
Country: Sweden

Publications

  1. ncbi Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe
    P Ljungman
    Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 37:439-49. 2006
  2. ncbi Prevention and treatment of viral infections in stem cell transplant recipients
    Per Ljungman
    Department of Haematology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Br J Haematol 118:44-57. 2002
  3. ncbi Beta-herpesvirus challenges in the transplant recipient
    Per Ljungman
    Karolinska Institutet, SE 14186 Stockholm, Sweden
    J Infect Dis 186:S99-S109. 2002
  4. ncbi Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation
    Per Ljungman
    Hematology Center, Karolinska University Hospital, SE 14186 Stockholm, Sweden
    Haematologica 91:78-83. 2006
  5. ncbi Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis
    Per Ljungman
    Department of Hematology, Huddinge University Hospital, SE 14186 Stockholm, Sweden
    Blood 102:4255-60. 2003
  6. ncbi Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study
    P Ljungman
    Department of Hematology, Huddinge University Hospital, 14186, Stockholm, Sweden
    Support Care Cancer 11:739-41. 2003
  7. ncbi Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction
    Per Ljungman
    Department of Hematology, Huddinge University Hospital, Karolinska Institutet, SE 14186 Stockholm, Sweden
    Br J Haematol 125:107-16. 2004
  8. ncbi Management of CMV infections: recommendations from the infectious diseases working party of the EBMT
    P Ljungman
    Department of Haematology, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 33:1075-81. 2004
  9. ncbi Treatment of adenovirus infections in the immunocompromised host
    P Ljungman
    Department of Haematology, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden
    Eur J Clin Microbiol Infect Dis 23:583-8. 2004
  10. ncbi Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease
    P Ljungman
    Department of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 34:589-93. 2004

Detail Information

Publications117 found, 100 shown here

  1. ncbi Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe
    P Ljungman
    Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 37:439-49. 2006
    ..The introduction of alternative therapies has challenged well-established indications such as imatinib for chronic myeloid leukaemia. An updated report with revised tables and operating definitions is presented here...
  2. ncbi Prevention and treatment of viral infections in stem cell transplant recipients
    Per Ljungman
    Department of Haematology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Br J Haematol 118:44-57. 2002
  3. ncbi Beta-herpesvirus challenges in the transplant recipient
    Per Ljungman
    Karolinska Institutet, SE 14186 Stockholm, Sweden
    J Infect Dis 186:S99-S109. 2002
    ..Diagnosis and treatment of CMV infection is currently more advanced than for HHV-6 and HHV-7...
  4. ncbi Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation
    Per Ljungman
    Hematology Center, Karolinska University Hospital, SE 14186 Stockholm, Sweden
    Haematologica 91:78-83. 2006
    ..Cytomegalovirus (CMV) disease remains an important complication of allogeneic stem cell transplantation (SCT). We studied viral load kinetics and correlated the viral load and other transplant factors with the development of CMV disease...
  5. ncbi Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis
    Per Ljungman
    Department of Hematology, Huddinge University Hospital, SE 14186 Stockholm, Sweden
    Blood 102:4255-60. 2003
    ..Our data suggest that donor CMV status influences outcome of unrelated SCT. For a CMV-seropositive patient, a seropositive donor might be preferable...
  6. ncbi Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study
    P Ljungman
    Department of Hematology, Huddinge University Hospital, 14186, Stockholm, Sweden
    Support Care Cancer 11:739-41. 2003
    ..Additional studies are needed to assess efficacy of this approach in the prevention of HZ...
  7. ncbi Risk of cytomegalovirus transmission by blood products to immunocompromised patients and means for reduction
    Per Ljungman
    Department of Hematology, Huddinge University Hospital, Karolinska Institutet, SE 14186 Stockholm, Sweden
    Br J Haematol 125:107-16. 2004
  8. ncbi Management of CMV infections: recommendations from the infectious diseases working party of the EBMT
    P Ljungman
    Department of Haematology, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 33:1075-81. 2004
  9. ncbi Treatment of adenovirus infections in the immunocompromised host
    P Ljungman
    Department of Haematology, Karolinska University Hospital Huddinge, 14186 Stockholm, Sweden
    Eur J Clin Microbiol Infect Dis 23:583-8. 2004
    ..New strategies, including pre-emptive therapy, should be tested in prospective, clinical trials. New agents and adoptive transfer of specific T-cells to adenovirus might improve the current situation...
  10. ncbi Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease
    P Ljungman
    Department of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 34:589-93. 2004
    ..Since measles is again circulating in many countries and measles is a serious infection after SCT, vaccination should be considered...
  11. ncbi Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients
    P Ljungman
    Department of Hematology, Karolinska University Hospital, Stockholm 14186, Sweden
    Bone Marrow Transplant 34:1067-9. 2004
    ..07). A total of 14 patients received a booster dose of an inactivated poliovirus vaccine and all responded. We conclude that poliovirus immunity is retained long term after revaccination in most patients after allogeneic SCT...
  12. ncbi Human herpesvirus-6 infection in solid organ and stem cell transplant recipients
    Per Ljungman
    Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
    J Clin Virol 37:S87-91. 2006
    ..No established therapy exists but both ganciclovir and foscarnet have been reported to have in vitro and in vivo efficacy against HHV-6...
  13. ncbi Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT
    P Ljungman
    Department of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 35:737-46. 2005
    ..The EBMT produced recommendations for vaccination of SCT recipients published in Bone Marrow Transplantation in 1995. This paper updates the previous recommendations based on current knowledge...
  14. ncbi The value of CMV and fungal PCR for monitoring for acute leukaemia and autologous stem cell transplant patients
    Per Ljungman
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Scand J Infect Dis 37:121-7. 2005
    ..No antiviral therapy was give and both recovered. PCR for Aspergillus might be helpful for the diagnosis of pneumonia while neither CMV nor Candida PCR conferred diagnostic benefits in this study...
  15. ncbi Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study
    Per Ljungman
    Haematology Centre, Karolinska University Hospital, Stockholm, Sweden
    Br J Haematol 130:96-8. 2005
    ..Patients treated with monoclonal antibodies for lymphoma had very poor responses. We conclude that two doses of influenza vaccine do not improve the antibody response in patients with haematological malignancies...
  16. ncbi Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors
    Per Ljungman
    Department of Hematology, Huddinge University Hospital, Stockholm, Sweden
    Scand J Infect Dis 34:347-50. 2002
    ..Thus, this strategy can be safely used together with PCR monitoring and preemptive therapy...
  17. ncbi Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
    P Ljungman
    Department of Hematology, Huddinge University Hospital, Karolinska Institutet, Sweden
    Transplantation 66:1330-4. 1998
    ..Several preventive strategies against cytomegalovirus (CMV) disease have been developed during the last decade. These have frequently been used in combination, and it has been difficult to identify each strategy's contribution...
  18. ncbi Definitions of cytomegalovirus infection and disease in transplant recipients
    Per Ljungman
    Department of Hematology, Huddinge University Hospital, Karolinska Institutet, SE 14186 Stockholm, Sweden
    Clin Infect Dis 34:1094-7. 2002
    ..This study seeks to update the definitions of CMV on the basis of recent developments in diagnostic techniques, as well as to add to these definitions the concept of indirect effects caused by CMV...
  19. ncbi High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients
    P Ljungman
    Department of Haematology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Br J Haematol 111:774-81. 2000
    ..04) influenced HHV-6 DNA levels. HHV-6 viral load was significantly correlated with delayed platelet engraftment in both univariate (P < 0.01) and multivariate analysis, and to the number of platelet transfusions...
  20. ncbi Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
    P Ljungman
    Huddinge University Hospital, Stockholm, Sweden St Anna Kinderspital, Vienna, Austria
    Blood 97:388-92. 2001
    ..6%) patients. Cidofovir can be considered as second-line therapy in patients with CMV disease failing previous antiviral therapy. However, additional studies are needed before CDV can be recommended for preemptive therapy...
  21. ncbi Immune reconstitution and viral infections after stem cell transplantation
    P Ljungman
    Department of Hematology, Huddinge University Hospital, Sweden
    Bone Marrow Transplant 21:S72-4. 1998
    ..For this group of patients new innovative preventive and therapeutic strategies are needed...
  22. ncbi Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants
    Per Ljungman
    Department of Haematology, Huddinge University Hospital, Stockholm, Sweden
    Blood 99:3050-6. 2002
    ..Survival was similar in each group. Valacyclovir prophylaxis provides a clinically valuable intervention but must be part of an overall strategy for CMV prevention in BMT...
  23. ncbi Prophylaxis against herpesvirus infections in transplant recipients
    P Ljungman
    Department of Haematology, Huddinge University Hospital, Karolinska Institutet, Sweden
    Drugs 61:187-96. 2001
    ..Finally cidofovir is an interesting agent with broad spectrum antiherpesvirus efficacy. However, because of the drug's toxicity profile, further studies are needed...
  24. ncbi Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus
    Kajsa Larsson
    Division for Hematology, Department of Medicine, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Transplantation 77:526-31. 2004
    ..The aim of this study was to investigate the relationship between cytomegalovirus (CMV) and extensive chronic graft-versus-host disease (GvHD) after allogeneic stem-cell transplantation (SCT)...
  25. ncbi Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors
    Petter Svenberg
    Centre for Allogenic Stem Cell Transplantation, Department of Paediatrics, Karolinska University Hospital, Huddinge, SE 14186 Stockholm, Sweden
    Biol Blood Marrow Transplant 10:877-82. 2004
    ..We conclude that HSCT with HLA-A, -B, and -DRbeta1 genomically matched unrelated donors in combination with antithymocyte globulin in the conditioning regimen gives encouraging results in patients with SAA or IEM...
  26. ncbi Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
    Mats Remberger
    Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Biol Blood Marrow Transplant 8:674-82. 2002
    ..Patients with previous acute GVHD grades II to IV may benefit from more aggressive initial treatment. This possibility would have to be examined in clinical trials...
  27. doi A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors
    Mats Remberger
    Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital, Stockholm, Sweden
    Clin Transplant 27:E368-74. 2013
    ..001) were correlated to relapse, and low-dose ATG was associated with improved RFS (p < 0.05). A high dose (8 mg/kg) of ATG in RIC HSCT with unrelated donors increased the risk for relapse and reduced the RFS...
  28. doi Factors with an impact on chimerism development and long-term survival after umbilical cord blood transplantation
    Sofia Berglund
    Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Transplantation 94:1066-74. 2012
    ..Umbilical cord blood transplantation (UCBT) is increasingly used and produces similar results to matched unrelated donor transplantation...
  29. pmc NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation
    Andreas T Björklund
    Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Blood 115:2686-94. 2010
    ..Our results provide evidence against the emergence of alloreactive NK cells in HLA-identical allogeneic SCT...
  30. ncbi Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center
    Olle Ringden
    Center for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Transplantation 81:718-25. 2006
    ..Allogeneic hematopoietic stem cell transplantation (ASCT) is a possible cure for many inherited disorders...
  31. doi Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy
    Lena von Bahr
    Haematology Centre, Department of Clinical Immunology, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Biol Blood Marrow Transplant 18:557-64. 2012
    ..01). We conclude that treatment with early-passage MSCs improved survival in patients with therapy-resistant GVHD. Death from infection was common in MSC-treated patients, but there was no increase in leukemia relapse...
  32. ncbi Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome
    Gayane Avetisyan
    Division of Hematology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Transplantation 88:1222-6. 2009
    ..We aimed to determine the frequency, risk factors, and outcome of RSV infection in allo-HSCT recipients...
  33. doi Bacteremia in Swedish hematological patients with febrile neutropenia: bacterial spectrum and antimicrobial resistance patterns
    Carl Aust
    Department of Medicine, Solna, Infectious Disease Unit, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Scand J Infect Dis 45:285-91. 2013
    ....
  34. doi Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions
    Darius Sairafi
    Center for Allogeneic Stem Cell Transplantation, Department of Medicine at Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Biol Blood Marrow Transplant 16:1728-37. 2010
    ..In contrast, time between ASCT and start of DLI treatment had no significant influence on the risk of developing aGVHD. To conclude, monitoring of leukemia lineage-specific chimerism is of utmost importance for DLI response after ASCT...
  35. ncbi Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia
    Anna Nordlander
    Center for Allogenic Stem Cell Transplantation and Department of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Biol Blood Marrow Transplant 10:195-203. 2004
    ..01), and an HLA-matched donor (P=.01). The association between herpes simplex virus infection and a low frequency of relapse is a new observation and may indicate that viral antigens play a role in the induction of an antileukemic effect...
  36. ncbi Clinical tolerance after allogeneic hematopoietic stem cell transplantation: a study of influencing factors
    Patrik Hentschke
    Centre for Allogeneic Stem Cell Transplantation, Huddinge University Hospital, Stockholm, Sweden Patrik Hentschke transpl hs sll se
    Transplantation 73:930-6. 2002
    ..However, this phenomenon has rarely been studied...
  37. pmc Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies
    Katarina Le Blanc
    Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet, Stockholm, Sweden
    Biol Blood Marrow Transplant 15:1108-15. 2009
    ..81, P=.02) and aGVHD (HR 0.84, P=.05). These results indicate that LC30 is an independent prognostic factor for transplant outcome in matched unrelated SCT for myelogenous malignancies...
  38. ncbi Factors influencing cytomegalovirus seropositivity in stem cell transplant patients and donors
    Per Ljungman
    Hematology Center, Karolinska University Hospital, Stockholm, Sweden
    Haematologica 92:1139-42. 2007
    ..Adjusted for patient serostatus, the risk of a donor being seropositive was higher in females (p<0.001) and older donors (p<0.001)...
  39. ncbi A real-time TaqMan PCR for routine quantitation of cytomegalovirus DNA in crude leukocyte lysates from stem cell transplant patients
    Zhibing Yun
    Department of Clinical Virology, Karolinska Institutet, Huddinge University Hospital, F68, S 141 86 Huddinge, Stockholm, Sweden
    J Virol Methods 110:73-9. 2003
    ..This TaqMan PCR was highly sensitive, reproducible, and stable and has served a useful tool for monitoring CMV DNA levels in large number of clinical samples in a routine diagnostic setting for over 1 year...
  40. ncbi Identification of species of viridans group streptococci in clinical blood culture isolates by sequence analysis of the RNase P RNA gene, rnpB
    Katarina Westling
    Department of Medicine, Division of Infectious Diseases, I 73, Karolinska Institutet, Karolinska University Hospital Huddinge, SE 141 86 Stockholm, Sweden
    J Infect 56:204-10. 2008
    ....
  41. ncbi Risk assessment in haematopoietic stem cell transplantation: viral status
    Per Ljungman
    Hematology Center, Karolinska University Hospital, Karolinska Institute, SE 14186 Stockholm, Sweden
    Best Pract Res Clin Haematol 20:209-17. 2007
    ..The aim of this review is to describe current knowledge regarding recipient and donor serological status for viral infections...
  42. ncbi The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen
    Geraldine Giraud
    Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    Haematologica 91:401-4. 2006
    ..02). Finally, hemorrhagic cystitis and BK-viruria were less common in patients receiving RIC, rather than full conditioning (p<0.01 and p<0.01, respectively)...
  43. ncbi Full myeloablative conditioning and an unrelated HLA mismatched donor increase the risk for BK virus-positive hemorrhagic cystitis in allogeneic hematopoetic stem cell transplanted patients
    Tina Dalianis
    Department of Oncology Pathology, Karolinska Institutet, Cancer Center Karolinska R8 01, Karolinska Hospital, 171 76 Stockholm, Sweden
    Anticancer Res 31:939-44. 2011
    ....
  44. ncbi Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?
    Olle Ringden
    Centre for Allogeneic Stem Cell Transplantation, Division of Clinical Immunology, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Biol Blood Marrow Transplant 10:128-34. 2004
    ..The 5-year survival was 72%, 48%, and 30% with 0, 1, and 2 risk factors, respectively. We concluded that unrelated hematopoietic stem cell transplantation may be improved if an optimal donor and immunosuppression are chosen...
  45. ncbi A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies
    Honar Cherif
    Department of Medicine, Division of Haematology, Karolinska Hospital and Institute, Stockholm, Sweden
    Scand J Infect Dis 36:593-600. 2004
    ..Early discontinuation of antibiotic therapy in 31 patients with FUO 48 h after defervescence was not associated with an increased rate of fever relapse or mortality compared with a subgroup of 29 patients where therapy was continued...
  46. doi Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009
    P Ljungman
    Department of Haematology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 45:219-34. 2010
    ..The introduction of alternative therapies, such as imatinib for CML, has challenged well-established indications. An updated report with revised tables and operating definitions is presented...
  47. ncbi Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation
    P Ljungman
    Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden
    Bone Marrow Transplant 31:481-6. 2003
    ..We conclude that cidofovir may be useful against adenovirus after allogeneic hematopoietic stem cell transplantation but additional studies are needed...
  48. ncbi Rapid salvage treatment with virus-specific T cells for therapy-resistant disease
    Michael Uhlin
    Therapeutic Immunology Unit, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden
    Clin Infect Dis 55:1064-73. 2012
    ..If primary antiviral therapy fails or cannot be tolerated, adoptive therapy with virus-specific cytotoxic T cells (CTL) can be utilized...
  49. ncbi Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease: implications for its use?
    Stefan Deneberg
    Centre of Haematology M54, Karolinska University Hospital, Huddinge, Stockholm 141 86, Sweden
    Med Oncol 24:354-6. 2007
    ..Although no definite conclusions can be drawn from one case this might have implications for the use of Rituximab in cGVHD in ALL patients...
  50. pmc Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients
    Per Ljungman
    Dept of Haematology, Karolinska University Hospital, Stockholm, Sweden
    Haematologica 96:1231-5. 2011
    ..3%) died from A/H1N1 infection or its complications. Neutropenia (P=0.03) and patient age (P=0.04) were significant risk factors for death. The 2009 A/H1N1 influenza pandemic caused severe complications in stem cell transplant recipients...
  51. ncbi Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells
    K Le Blanc
    Hematology Center, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Leukemia 21:1733-8. 2007
    ..Thus, co-transplantation of MSC resulted in fast engraftment of absolute neutrophil count (ANC) and platelets and 100% donor chimerism, even in three patients regrafted for graft failure/rejection...
  52. ncbi Human herpesvirus 6 infection and cytomegalovirus-specific lymphoproliferative responses in allogeneic stem cell transplant recipients
    F Z Wang
    Department of Hematology, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Bone Marrow Transplant 30:521-6. 2002
    ..001). Our data indicate the possibility that HHV-6 can suppress the development of CMV-specific immune responses and thereby could predispose to development of late CMV disease...
  53. doi CMV: a warrior against leukemia?
    Per Ljungman
    Karolinska University Hospital, Sweden
    Blood 122:1101-2. 2013
    ..In this issue of Blood, Green et al provide additional information supporting that cytomegalovirus (CMV) reduces leukemia relapse after allogeneic stem cell transplantation...
  54. pmc NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs
    Vivien Beziat
    Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Blood 121:2678-88. 2013
    ..These results provide new insight into the diversity of KIR repertoire and its adaptation to virus infection, suggesting a role for both activating and inhibitory KIRs in immunity to CMV infection...
  55. ncbi Cytomegalovirus in hematopoietic stem cell transplant recipients
    Per Ljungman
    Department of Hematology, Karolinska University Hospital, S 14186 Stockholm, Sweden
    Infect Dis Clin North Am 24:319-37. 2010
    ..This article examines the clinical manifestations of and risk factors for cytomegalovirus (CMV). Prevention of CMV infection and disease are also explored. Antiviral resistance and management of CMV are examined...
  56. ncbi A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation
    Benjamin Edvinsson
    Swedish Institute for Infectious Disease Control, Karolinska University Hospital Huddinge, Stockholm, Sweden
    APMIS 116:345-51. 2008
    ..These two patients were seropositive for T. gondii. We concluded that monitoring for T. gondii DNA in peripheral blood samples using PCR might be a valuable method for identifying toxoplasma-seropositive stem cell transplant recipients...
  57. ncbi Symptom occurrence, symptom intensity, and symptom distress in patients undergoing high-dose chemotherapy with stem-cell transplantation
    Joacim Larsen
    Department of Nursing, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Cancer Nurs 27:55-64. 2004
    ..To use an instrument that distinguishes between these aspects of the symptom experience may help health care professionals to support the patients through the SCT-process...
  58. ncbi Factors associated with poor general health after stem-cell transplantation
    Joacim Larsen
    Division of Nursing, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 23300, 141 83 Huddinge, Stockholm, Sweden
    Support Care Cancer 15:849-57. 2007
    ..To describe functional status (FS), general health (GH) and symptom distress (SD) from admission to 1 year post-SCT and to identify medical, demographic, and/or patient-reported outcome variables associated with patient-perceived GH...
  59. ncbi Quantification of adenovirus DNA in unrelated donor hematopoietic stem cell transplant recipients
    I Gustafson
    Department of Medicine, Infectious Disease Unit, B2 00, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, S 171 76 Stockholm, Sweden
    J Clin Virol 43:79-85. 2008
    ..Adenovirus (AdV) infection is a life threatening condition in immunosuppressed patients. Quantitative AdV assays can improve the clinical management of these patients...
  60. ncbi Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT
    G Avetisyan
    Division of Haematology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Bone Marrow Transplant 40:865-9. 2007
    ..01). There was no effect as regards the type of conditioning, donor type, stem cell source or acute GVHD. Monitoring the immunity of SCT patients may allow more targeted use of antiviral therapy...
  61. ncbi Effectiveness of ganciclovir against human herpesvirus-6 excreted in saliva in stem cell transplant recipients
    P Ljungman
    Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 39:497-9. 2007
    ..49 (s.e. 0.31) log(10)/week in patients receiving ganciclovir whereas it increased 0.15 (s.e. 0.17) log(10)/week in episodes without antiviral therapy (P=0.04). We conclude that ganciclovir can decrease the HHV-6 viral load in saliva...
  62. doi Analysis of donor and recipient ABO incompatibility and antibody-associated complications after allogeneic stem cell transplantation with reduced-intensity conditioning
    Emma Watz
    Therapeutic Immunology Unit, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden Electronic address
    Biol Blood Marrow Transplant 20:264-71. 2014
    ..Our results suggest that occurrence of unexpected ABO antibodies after HSCT warrant a wider investigation individual to find the underlying cause. ..
  63. pmc Viral findings in adult hematological patients with neutropenia
    Lars Ohrmalm
    Department of Medicine, Solna, Infectious Disease Unit, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    PLoS ONE 7:e36543. 2012
    ..In this study, we have prospectively investigated the prevalence of a broad range of respiratory viruses in nasopharyngeal aspirate (NPA) as well as viruses that commonly reactivate after allogeneic HSCT...
  64. doi Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study
    Mats Remberger
    Center for Allogeneic Stem Cell Transplantation, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden
    Biol Blood Marrow Transplant 17:1688-97. 2011
    ..The problem of relapse still has to be remedied. Thus, several different developments together have resulted in significantly lower TRM and improved survival after HSCT over the last few years...
  65. ncbi Viral infections: current diagnosis and treatment
    Per Ljungman
    Huddinge University Hospital, Stockholm, Sweden
    Hematol J 5:S63-8. 2004
  66. ncbi Viridans group streptococci in blood culture isolates in a Swedish university hospital: antibiotic susceptibility and identification of erythromycin resistance genes
    Katarina Westling
    Department of Medicine, Division of Infectious Diseases, Karolinska University Hospital Huddinge, Karolinska Institutet, I 73, SE 141 86 Stockholm, Sweden
    Int J Antimicrob Agents 28:292-6. 2006
    ..Susceptibility to newer antibiotics was high; all strains were susceptible to dalbavancin, daptomycin, linezolid and vancomycin...
  67. ncbi Molecular monitoring of viral infections after hematopoietic stem cell transplantation
    Per Ljungman
    Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
    Int J Hematol 91:596-601. 2010
    ..Standardized assays are lacking for these viruses and additional studies are needed...
  68. ncbi Allogeneic stem cell transplantation: low immunoglobulin levels associated with decreased survival
    A C Norlin
    Department of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 41:267-73. 2008
    ..04) and an increased incidence of transplant-related mortality (27 vs 9%, P<0.01). IgG levels generally increase after SCT. Persistent low levels of IgG are a risk factor for death after SCT...
  69. ncbi A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning
    M Hassan
    Laboratory of Hematology, Division of Hematology, Department of Medicine, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 30:833-41. 2002
    ..Moreover, the novel liposomal form of busulphan showed a favorable toxicity profile and seems safe as a part of the high-dose therapy prior to SCT...
  70. ncbi Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation
    G Avetisyan
    Department of Medicine, Division of Haematology, Karolinska Institutet, Karolinska University Hospital in Huddinge, Stockholm 14186, Sweden
    Bone Marrow Transplant 38:687-92. 2006
    ..Recovery of CMV-specific immunity might be delayed in patients with CMV disease. These observations suggest that detection of CMV-specific T-cells is useful in assessing the immunity against CMV...
  71. ncbi Real-time monitoring of cytomegalovirus infections after stem cell transplantation using the TaqMan polymerase chain reaction assays
    Z Yun
    Division of Clinical Virology, Huddinge University Hospital, Karolinska Institutet, Sweden
    Transplantation 69:1733-6. 2000
    ..Real-time monitoring of cytomegalovirus (CMV) infections in transplant patients demands a rapid and high-throughput CMV DNA quantification method...
  72. ncbi Donor cytomegalovirus status influences the outcome of allogeneic stem cell transplant: a study by the European group for blood and marrow transplantation
    Per Ljungman
    Department of Hematology, Karolinska University Hospital, and Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
    Clin Infect Dis 59:473-81. 2014
    ..However, the importance of donor serostatus in CMV-seropositive patients is controversial...
  73. doi Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation
    Gayane Avetisyan
    Division of Hematology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    Transplantation 86:257-63. 2008
    ..Measurement of cellular and humoral immunological responses might increase our understanding of how to estimate a protective response to influenza vaccination...
  74. ncbi Human herpesvirus 6 DNA in cerebrospinal fluid specimens from allogeneic bone marrow transplant patients: does it have clinical significance?
    F Z Wang
    BMT Program, Huddinge University Hospital, Karolinska Institute, Sweden
    Clin Infect Dis 28:562-8. 1999
    ..Four cases' conditions were improved or they were cured after treatment with either ganciclovir or foscarnet, and one case died of CNS disease despite foscarnet treatment...
  75. ncbi The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors
    M Remberger
    Department of Clinical Immunology, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 30:761-8. 2002
    ..Overall and relapse-free survival were not improved by the occurrence of acute GVHD...
  76. ncbi CMV retinitis after allogeneic bone marrow transplantation: a report of five cases
    Kajsa Larsson
    Department of Haematology, Huddinge University Hospital, SE 14186 Stockholm, Sweden
    Transpl Infect Dis 4:75-9. 2002
    ..We conclude that CMV retinitis is a rare but important complication to allogeneic blood stem cell transplantation...
  77. ncbi Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983--93 and 1994--8 at European Group for Blood and Marrow Transplantation centres
    G Gahrton
    Department of Medicine, Huddinge Hospital, Sweden
    Br J Haematol 113:209-16. 2001
    ..Better supportive treatment and more frequent use of cytokines may also play a role. The improvement in survival was not directly related to the increased use of PBSCs...
  78. ncbi Reduced susceptibility to penicillin of viridans group streptococci in the oral cavity of patients with haematological disease
    K Westling
    Division of Infectious Diseases, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Clin Microbiol Infect 10:899-903. 2004
    ....
  79. ncbi The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants
    G Gahrton
    Department of Medicine, Karolinska Institute and Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 35:609-17. 2005
    ..Therefore, a female donor is as good as a male one for male patients, while for female patients gender disparity is a negative factor for outcome...
  80. ncbi Respiratory virus infections in stem cell transplant patients: the European experience
    P Ljungman
    Department of Hematology, Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden
    Biol Blood Marrow Transplant 7:5S-7S. 2001
    ..1%. In an 18-month extension, an additional 53 patients with CRV were identified. Results for the combined data were similar to those from the first phase of the study...
  81. doi The socioeconomic and psychosocial circumstances of adult long-term survivors of hematopoietic stem cell transplantation in childhood
    Catharina M Löf
    Department of Pediatrics, CLINTEC, Karolinska Institutet, Karolinska University Hospital, Huddinge, Sweden
    Pediatr Transplant 15:691-8. 2011
    ..These results indicate the importance of recognizing and attempting to tackle the possible cumulative disadvantage of problems that affect the adult following SCT in childhood...
  82. ncbi Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients
    Per Ljungman
    Hematology Center, Karolinska University Hospital, S 14186 Stockholm, Sweden
    J Clin Virol 35:493-5. 2006
    ..Several techniques have been used and each has advantages and disadvantages...
  83. doi Decreased IL-7 signaling in T cells from patients with PTLD after allogeneic HSCT
    Hamdy Omar
    Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
    J Immunother 34:390-6. 2011
    ..Reduced IL-7 responsiveness will aid to monitor patients after HSCT for increased risk to develop EBV-associated PTLD...
  84. doi Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction
    H Omar
    Department of Medicine, Huddinge, Division of Haematology, Karolinska Institutet, Stockholm, Sweden
    Transpl Infect Dis 11:393-9. 2009
    ..The likelihood of PTLD is increased in the presence of specific risk factors. Monitoring of EBV DNA load and early administration of rituximab in patients with high EBV loads is recommended for high-risk patients...
  85. ncbi BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts
    G Giraud
    Department of Oncology Pathology, Karolinska Institutet, Stockholm, Sweden
    Bone Marrow Transplant 41:737-42. 2008
    ..6; P=0.03). However, when analysing HSCT performed with URD or RD grafts separately, BKV (OR 8.5; 95% CI 1.8-19.3; P=0.004) and MC (OR 5.9; 95% CI 1.3-11.3; P=0.009) increased the risk for HC only with a URD, but not with an RD graft...
  86. ncbi Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT
    P Ljungman
    Department of Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 42:227-40. 2008
    ..Works presented only as abstracts were used to a very limited extent. The quality of evidence and level of recommendation were graded according to the Center for Disease Control (CDC) criteria...
  87. ncbi Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases
    O Ringden
    Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 39:383-8. 2007
    ..03). Treatment-related mortality was 4 and 15%, and 5-year survival was 89 and 85% in the FBC and MC groups. Although survival was similar, FBC is a promising alternative to MC in non-malignant disorders...
  88. doi Vaccination of immunocompromised patients
    Per Ljungman
    Department of Haematology, Karolinska University Hospital, Division of Haematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
    Clin Microbiol Infect 18:93-9. 2012
    ..However, vaccination against pneumococci, Haemophilus influenzae and influenza are generally recommended. Live vaccines must be used with care because the risk for vaccine-associated disease exists...
  89. pmc Cytomegalovirus in hematopoietic stem cell transplant recipients
    Per Ljungman
    Department of Hematology, Karolinska University Hospital, S 14186 Stockholm, Sweden Divison of Hematology, Department of Medicine Huddinge, Karolinska Institutet, S 14186 Stockholm, Sweden
    Hematol Oncol Clin North Am 25:151-69. 2011
    ..This article examines the clinical manifestations of and risk factors for cytomegalovirus (CMV). Prevention of CMV infection and disease are also explored. Antiviral resistance and management of CMV are examined...
  90. ncbi Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group
    Ulla Axdorph
    Division of Haematology, Department of Medicine, Karolinska Hospital and Institutet, Stockholm, Sweden
    Br J Haematol 118:1048-54. 2002
    ..Subsequent SCT/ASCT was feasible for half of the responders (< 65 years), and one individual underwent double ASCT. Novel therapeutic options for CML patients in AP/BP are needed...
  91. pmc Association between a high BK virus load in urine samples of patients with graft-versus-host disease and development of hemorrhagic cystitis after hematopoietic stem cell transplantation
    G Bogdanovic
    Department of Oncology Pathology, Karolinska Institute, Hudding University Hospital, Stockholm, Sweden
    J Clin Microbiol 42:5394-6. 2004
    ..BKV load in combination with acute GVHD discriminated the best, while BKV and viral load alone, but not GVHD, still showed predictive ability for HC...
  92. ncbi Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study
    J Bergh
    Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Lancet 356:1384-91. 2000
    ..We then did a randomised trial to compare this individually tailored FEC regimen with conventional adjuvant chemotherapy followed by consolidation with high-dose chemotherapy with stem-cell support...
  93. ncbi Antibodies to human herpesvirus 8 latent and lytic antigens in blood donors and potential high-risk groups in Sweden: variable frequencies found in a multicenter serological study
    M Enbom
    Department of Virology, Swedish Institute for Infectious Disease Control, Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden
    J Med Virol 62:498-504. 2000
    ..1 ELISA to be highly specific and also showed a good agreement between two of the immunofluorescence assays. However, generally there was a poor correlation for positive results, indicating the need of further methodological development...
  94. ncbi The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation
    C Nilsson
    Department of Medicine, Huddinge University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 31:429-35. 2003
    ..We conclude that metronidazole should not be administered simultaneously with Bu to avoid the high plasma levels of Bu, which may lead to severe toxicity and/or treatment related mortality...
  95. ncbi Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation
    A Bjorklund
    Hematology Center, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 40:1055-62. 2007
    ..In conclusion, infections occurring later than 6 months after HSCT are important contributors to late non-relapse mortality after HSCT. CMV infection or acute GVHD markedly increase the risk...
  96. ncbi Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients
    G Avetisyan
    Department of Medicine, Division of Hematology, Karolinska Institutet, Stockholm, Sweden
    Bone Marrow Transplant 36:411-5. 2005
    ..In conclusion, our results suggest that the ELISPOT assay might be used as a complement to serology for monitoring of future influenza vaccine studies in SCT patients...
  97. ncbi Comparison of general vs regional anaesthesia for BM harvesting: a retrospective study of anaesthesia-related complications
    M Machaczka
    Department of Haematology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Bone Marrow Transplant 45:53-61. 2010
    ..01) and in female donors compared with male donors (29 vs 14%, P=0.002). In conclusion, both GA and RA are comparable with regard to BMH. Nevertheless, non-severe intra- and postoperative events were frequent...
  98. ncbi Streptococcus viridans septicaemia: a comparison study in patients admitted to the departments of infectious diseases and haematology in a university hospital
    Katarina Westling
    Department of Infectious Diseases, Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden
    Scand J Infect Dis 34:316-9. 2002
    ..S. sanguis was the most common subtype (18/47; 38%) in Group A and S. mitis was the major subtype (51/74; 69%) in Group B...
  99. doi DNA variants, plasma levels and variability of interleukin-6 in myocardial infarction survivors: results from the AIRGENE study
    Petter Ljungman
    Dept of Cardiology, Karolinska Institutet, Stockholm South Hospital, Stockholm, Sweden
    Thromb Res 124:57-64. 2009
    ..Increased levels of interleukin 6 (IL-6), a marker for systemic inflammation, have been associated with cardiovascular morbidity and mortality...
  100. doi Health-related quality of life in adult survivors after paediatric allo-SCT
    C M Löf
    Department of Paediatrics, CLINTEC, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
    Bone Marrow Transplant 43:461-8. 2009
    ..To conclude, childhood SCT did not negatively affect overall health for most of these adult long-term survivors, although poorer HRQoL with psychological and cognitive problems are common...
  101. ncbi Symptom distress, functional status and health-related quality of life before high-dose chemotherapy with stem-cell transplantation
    J Larsen
    Department of Nursing, Karolinska Institutet, Stockholm, Sweden
    Eur J Cancer Care (Engl) 12:71-80. 2003
    ..Patients with advanced disease and patients with multiple myeloma were found to report more SD and poorer FS and HRQOL...